Cerixen® 150 mg (Ceritinib INN) – Everest Pharmaceuticals Ltd.
Targeted ALK Inhibitor for Advanced Non-Small Cell Lung Cancer
📌 Indications:
Cerixen® 150 mg is indicated for:
-
ALK-positive metastatic non-small cell lung cancer (NSCLC)
-
Patients with disease progression following crizotinib treatment
-
First-line treatment of ALK-positive advanced NSCLC
💊 Pharmacology:
Ceritinib is a highly selective ALK tyrosine kinase inhibitor. It blocks the activity of ALK fusion proteins responsible for uncontrolled cell growth and proliferation. By inhibiting ALK signaling pathways, Cerixen® suppresses tumor progression and induces cancer cell death.
💉 Dosage & Administration:
-
Recommended dose: 450 mg once daily with food (three 150 mg capsules).
-
Continue treatment until disease progression or unacceptable toxicity occurs.
-
Dose modifications may be necessary based on adverse reactions.
-
Use under the supervision of an experienced oncologist.
⚠️ Precautions & Warnings:
-
Monitor liver function tests regularly.
-
Use caution in patients with interstitial lung disease or pneumonitis.
-
Monitor blood glucose levels in diabetic patients.
-
QT interval prolongation and bradycardia may occur.
-
Gastrointestinal toxicity is common and should be managed appropriately.
❌ Contraindications:
-
Hypersensitivity to Ceritinib or any component of the formulation.
🤰 Pregnancy & Lactation:
-
May cause fetal harm when administered during pregnancy.
-
Effective contraception is recommended during treatment.
-
Breastfeeding should be discontinued during therapy and for at least two weeks after the last dose.
⚕️ Side Effects:
Common adverse effects include:
-
Diarrhea
-
Nausea and vomiting
-
Abdominal pain
-
Fatigue
-
Elevated liver enzymes
-
Hyperglycemia
-
Decreased appetite
Serious adverse reactions may include:
-
Hepatotoxicity
-
Interstitial lung disease/pneumonitis
-
QT prolongation
-
Severe gastrointestinal toxicity
🧊 Storage Conditions:
-
Store below 30°C in a dry place.
-
Protect from light and moisture.
-
Keep out of reach of children.
